Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA.
Tous les auteurs :
Delfau-Larue MH, de Leval L, Joly B, Plonquet A, Challine D, Parrens M, Delmer A, Salles G, Morschhauser F, Delarue R, Brice P, Bouabdallah R, Casasnovas O, Tilly H, Gaulard P, Haioun C
In angioimmunoblastic T-cell lymphoma, symptoms linked to B-lymphocyte activation are common, and variable numbers of CD20(+) large B-blasts, often infected by Epstein-Barr virus, are found in tumor tissues. We postulated that the disruption of putative B-T interactions and/or depletion of the Epstein-Barr virus reservoir by an anti-CD20 monoclonal antibody (rituximab) could improve the clinical outcome produced by conventional chemotherapy.
Aged, Antibodies, Monoclonal, Murine-Derived, administration & dosage, Antineoplastic Combined Chemotherapy Protocols, adverse effects, B-Lymphocytes, drug effects, Cyclophosphamide, adverse effects, Doxorubicin, adverse effects, Female, Humans, Immunoblastic Lymphadenopathy, drug therapy, Lymphoma, T-Cell, drug therapy, Male, Middle Aged, Neoplasm Staging, Prednisone, adverse effects, Rituximab, Treatment Outcome, Vincristine, adverse effects
Haematologica. 2012 Oct;97(10):1594-602